Watch for Patients on the Parkinson's Med Nourianz

February 2020

Istradefylline (Nourianz, NUR-ee-anz) will be the first NON-dopaminergic "adenosine antagonist" for Parkinson's disease.

It's a once-daily add-on for "off" episodes...when scheduled carbidopa/levodopa wears off between doses and symptoms (rigidity, tremor, etc) return, especially as Parkinson's progresses.

But istradefylline doesn't seem to reduce "off" time more than dopaminergic add-ons...COMT inhibitors (entacapone, etc), dopamine agonists (pramipexole, etc), or MAO-B inhibitors (rasagiline, etc).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Seizures Consider Levetiracetam for Benzo-Resistant Status Epilepticus
New Drugs Save Recarbrio as a Last Resort for Resistant Infections
Emergency Medicine Be Ready to Manage Symptoms of Stimulant Toxicity
CPR Don't Expect to Add the Antiarrhythmic Bretylium to Crash Carts
Med Administration Know Whether to Redose Meds After Vomiting
New Drugs Expect Trikafta to Be a Game Changer for Cystic Fibrosis
Cardiology Help With Proper Use of Colchicine for Pericarditis
Hepatitis C Try to Limit Interruptions of Hep C Antivirals
New Drugs Watch for Patients on the Parkinson's Med Nourianz
Med Safety Recommend Eye Exams for Patients on Elmiron at Home

Watch for Patients on the Parkinson's Med Nourianz

Get unlimited access through an Enterprise license

Table of Contents